Literature DB >> 12163882

Abortifacient properties of aqueous extract of Carica papaya (Linn) seeds on female Sprague-Dawley rats.

O Oderinde1, C Noronha, A Oremosu, T Kusemiju, O A Okanlawon.   

Abstract

Experiments were conducted to investigate the abortifacient potential of aqueous extract of Carica papaya (Linn) seeds in female Sprague-Dawley rats. Oral doses of 100 and 800 mg/kg body weight were administered once a day on days 1-10 post-coitum. No significant differences in total body weight were found in foetuses exposed to these regimes. However, in the group treated with 100 mg/kg body weight, there was a significant increase (p < 0.05) in the implantation sites and foetal weight was significantly decreased (p < 0.05) compared to the controls. No dead or malformed foetuses were found. However, in the group treated with 800 mg/kg body weight, there was obvious vaginal bleeding but no treatment related increase in implantation sites compared with control. There was however, complete resorption of about 30% of the foetuses. The surviving foetuses were stunted when compared with the control but were without any external malformations. The results of the present investigations lead to the clear conclusion that low dose aqueous crude extract of Carica papaya (Linn) seeds does not adversely affect prenatal development. The altered toxicological profile indicates that the abortifacient property is a high dose side effect. The results indicate that Carica papaya toxicity can adversely affect the foetus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163882

Source DB:  PubMed          Journal:  Niger Postgrad Med J


  2 in total

1.  Fertility, developmental toxicity and teratogenicity in albino rats treated with methanol sub-fraction of Carica papaya seeds.

Authors:  S Shrivastava; A S Ansari; N K Lohiya
Journal:  Indian J Pharmacol       Date:  2011-07       Impact factor: 1.200

2.  Administration Dependent Antioxidant Effect of Carica papaya Seeds Water Extract.

Authors:  Elisa Panzarini; Majdi Dwikat; Stefania Mariano; Cristian Vergallo; Luciana Dini
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-25       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.